Barclays’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $144K | Sell |
15,445
-84,690
| -85% | -$763K | ﹤0.01% | 3869 |
|
|
2025
Q4 | $897K | Sell |
100,135
-232,308
| -70% | -$2.2M | ﹤0.01% | 3506 |
|
|
2025
Q3 | $3.16M | Buy |
332,443
+228,092
| +219% | +$2.29M | ﹤0.01% | 2521 |
|
|
2025
Q2 | $919K | Sell |
104,351
-330,339
| -76% | -$2.68M | ﹤0.01% | 3399 |
|
|
2025
Q1 | $3.26M | Buy |
434,690
+145,002
| +50% | +$1.15M | ﹤0.01% | 2261 |
|
|
2024
Q4 | $2.42M | Buy |
289,688
+232,089
| +403% | +$1.98M | ﹤0.01% | 2745 |
|
|
2024
Q3 | $400K | Buy |
57,599
+42,926
| +293% | +$291K | ﹤0.01% | 3911 |
|
|
2024
Q2 | $71.9K | Sell |
14,673
-10,933
| -43% | -$51.8K | ﹤0.01% | 4059 |
|
|
2024
Q1 | $149K | Sell |
25,606
-24,391
| -49% | -$150K | ﹤0.01% | 4265 |
|
|
2023
Q4 | $327K | Buy |
49,997
+44,032
| +738% | +$206K | ﹤0.01% | 4155 |
|
|
2023
Q3 | $28.8K | Sell |
5,965
-971
| -14% | -$4.85K | ﹤0.01% | 4072 |
|
|
2023
Q2 | $35.4K | Buy |
6,936
+6,827
| +6,263% | +$36.8K | ﹤0.01% | 3980 |
|
|
2023
Q1 | $600 | Sell |
109
-244
| -69% | -$1.29K | ﹤0.01% | 4945 |
|
|
2022
Q4 | $1.62K | Sell |
353
-1,304
| -79% | -$6.62K | ﹤0.01% | 5095 |
|
|
2022
Q3 | $10K | Buy |
+1,657
| New | +$9.38K | ﹤0.01% | 4319 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7190 |
|
|
2019
Q2 | – | Sell |
-18
| Closed | -$452 | – | 7332 |
|
|
2019
Q1 | $0 | Buy |
18
+12
| +200% | +$441 | ﹤0.01% | 7380 |
|
|
2018
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 7399 |
|
|
2018
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 7441 |
|
|
2018
Q2 | $1K | Hold |
6
| – | – | ﹤0.01% | 6902 |
|
|
2018
Q1 | $1K | Hold |
6
| – | – | ﹤0.01% | 6977 |
|
|
2017
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 7160 |
|
|
2017
Q3 | $0 | Sell |
6
-19
| -76% | -$1.01K | ﹤0.01% | 7082 |
|
|
2017
Q2 | $1K | Buy |
25
+19
| +317% | +$1.25K | ﹤0.01% | 6547 |
|
|
2017
Q1 | $0 | Sell |
6
-163
| -96% | -$9.9K | ﹤0.01% | 7022 |
|
|
2016
Q4 | $8K | Buy |
169
+165
| +4,125% | +$10.1K | ﹤0.01% | 5991 |
|
|
2016
Q3 | $0 | Sell |
4
-7
| -64% | -$498 | ﹤0.01% | 6828 |
|
|
2016
Q2 | $1K | Buy |
11
+6
| +120% | +$987 | ﹤0.01% | 6178 |
|
|
2016
Q1 | $1K | Sell |
5
-11
| -69% | -$2.66K | ﹤0.01% | 6015 |
|
|
2015
Q4 | $5K | Sell |
16
-78
| -83% | -$21.2K | ﹤0.01% | 5586 |
|
|
2015
Q3 | $29K | Buy |
+94
| New | +$28.8K | ﹤0.01% | 5304 |
|
Other funds holding ZVRA
WP
NCM
VCM
ACM
Barclays's ZVRA Position: Q1 2026 in Review
Barclays reduced its Zevra Therapeutics (ZVRA) stake by 85% in Q1 2026, selling an estimated $763K and leaving 15,445 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #3869.
Barclays first reported a position in ZVRA in Q3 2015 and has held it in 30 quarters since. The position peaked at $3.26M in Q1 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.
- Barclays held 15,445 shares of Zevra Therapeutics worth $144K as of Q1 2026.
- Barclays sold 84,690 Zevra Therapeutics shares in Q1 2026, an estimated $763K.
- Zevra Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3869 holding.
- Barclays first reported a position in Zevra Therapeutics in Q3 2015 and has held it in 30 quarters since.
- Barclays's Zevra Therapeutics position peaked at $3.26M in Q1 2025.
- 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.